- Nitrogen-containing heterocyclic compound as well as preparation method, pharmaceutical composition and application thereof
-
The invention provides a nitrogen-containing heterocyclic compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound as shownin a formula I which is described in the specification,
- -
-
-
- NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
-
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
- -
-
-
- PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS
-
There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.
- -
-
-
- PPAR AGONIST COMPOUNDS, PREPARATION AND USES
-
The present invention relates to novel PPAR agonist compounds as well as pharmaceutical compositions containing them. The compounds according to the invention are of quite particular therapeutic interest, notably for treating diabetes and/or dyslipidemias, as well as for preventing cardiovascular pathologies.
- -
-
Page/Page column 16
(2011/08/22)
-
- HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS
-
The invention relates to chemical compounds of formula (IB): or a salt thereof. In some embodiments, the invention relates to inhibitors of UDP-3-0 — (R-S-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein and their use in the prevention and/or treatment of Gram- negative bacterial infections.
- -
-
Page/Page column 88-89
(2010/09/18)
-
- N-(PYRIDIN-3-YL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
-
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can
- -
-
Page/Page column 36-37
(2010/11/08)
-
- PYRIDINE N-OXIDES AS ANTIVIRAL AGENTS
-
The present invention relates to pyridinone derivatives of formula (I) wherein Z represents C2-6 alkynyl, aryl or heteroaryl, any of which groups may be optionally substituted, and R1 represents hydrogen, C1-6alkyl, C
- -
-
-
- Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones
-
A series of spiro hydantoins derived from 8-azachromanones (2,3-dihydro-4H-pyrano[2,3-b]pyridin-4-ones) has been prepared and tested for aldose reductase inhibitory activity. The standard Bucherer-Bergs conditions had to be drastically modified to increas
- Sarges,Goldstein,Welch,Swindell,Siegel,Beyer
-
p. 1859 - 1865
(2007/10/02)
-
- Azolidinedione derivatives
-
A series of novel spiro-deteroazolones derived from a 2,3-dihydropryrano[2,3-b]pyridine ring system have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxazolidinediones, spiro-thiazolidinediones and spiro-imidazolidinediones derived from the aforesaid ring system. (4'S) (2'R)-6'-Chloro-2',3'-dihydro-2'-methyl-spiro-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]-2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.
- -
-
-
- Azolidinedione derivatives
-
Spiro-heteroazolones of formula wherein, Z is methylene, oxygen, sulfur or imino; Y is oxygen or sulfur; and -A=B-D=E- represents -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH or -CH=CH-CH=N-, or an N-oxide derivative thereof. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical member compounds include spiro-imides, spiro-oxa-zolidinediones, spiro-thiazolidinediones and spiro-imidazolidinediones derived from the aforesaid ring system. (4'S)(2'R)-6'-Chloro-2',3'-dihydro-2'-methyl--spiro-[imidazolidine-4,4'-4'H-pyrano[2,3-b]pyridine]--2,5-dione represents a typical and preferred member compound. Methods for preparing all these compounds from known starting materials are provided.
- -
-
-